Quantitative Perfusion
Sonia Borodzicz-Jazdzyk, MD, PhD
MD, PhD
1) Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands; 2) 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 02-097 Warsaw, Poland., Poland
Sonia Borodzicz-Jazdzyk, MD, PhD
MD, PhD
1) Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands; 2) 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 02-097 Warsaw, Poland., Poland
Caitlin E.M Vink, MD
MD
Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands
Amsterdam, Noord-Holland, Netherlands
Roel Hoek, MD
MD
Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands, Netherlands
Luuk H.G.A Hopman
PhD Student
Department of Cardiology, Amsterdam UMC
Amsterdam, Noord-Holland, Netherlands
Mark B. Hofman, PhD
PhD
Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands, Netherlands
Yvemarie B. Somsen, MD
MD
Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands, Netherlands
Ruben W. de Winter, MD
MD
Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands, Netherlands
Paul Knaapen, MD, PhD
Professor, MD, PhD
Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands
Amsterdam, Netherlands
Mitchel Benovoy, PhD
PhD
Area19 Medical Inc, Montreal, Canada, H2V 2X5
Montreal, Quebec, Canada
Marco J. Götte, MD, PhD
MD, PhD
Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands
Amsterdam, Noord-Holland, Netherlands
Final analysis was performed on 59 cases (14 cases were excluded due to technical issues and/or inadequate response to adenosine; age 62±12 years, 54% males, 59% with suspected CAD, 41% with prior history of CAD). Conventional visual CMR assessment diagnosed perfusion defects in 18 patients (30%). Retrospective assessment of automated MBF pixel-wise maps showed discrepancies vs. conventional visual approach in 26/59 cases (44%), including new diagnosis of ischemia (15/26; 58%; visual-/QP+ group, Figures 1,2), larger extent of ischemia (6/26; 23%), smaller extent of ischemia (2/26; 8%) and global MBF reduction (2/26; 8%). ICA was performed in 19 patients and CCTA in 6 patients within 6 months. Among 15 patients from visual-/QP+ group, only 3 underwent ICA, which confirmed obstructive CAD in 66% of cases. Cut-off value of stress MBF for detection of obstructive CAD was ≤1,68 ml/g/min. In total population, conventional visual assessment diagnosed 80 segments having perfusion defect, while in QP stress MBF≤1,68 ml/g/min was found in 199 segments.
Conclusion:
Incorporating of QP CMR into everyday clinical routine may detect ischemia in patients misdiagnosed by only visual assessment, as well as provide detailed information about the ischemic burden. Therefore, QP CMR may significantly alter the diagnostic and therapeutic pathway in real-world patients referred for stress perfusion CMR.